A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1b, open label, multi center, multi-dose trial designed to estimate the
maximum tolerated dose (MTD) and select the recommended dose for phase 2 (RP2D)
investigations of PF- 05082566 in combination with KW-0761 (mogamulizumab) in patients with
advanced solid tumors. Once the MTD of PF-05082566 administered in combination with KW-0761
is estimated (dose finding), one or more expansion cohorts of patients with selected advanced
solid tumors (dose-expansion ) will be enrolled to further characterize the combination in
term of safety profile, anti tumor activity, pharmacokinetics, pharmacodynamics and
biomarkers modulation.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Collaborators:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.
Treatments:
Antibodies, Monoclonal Immunoglobulin G Mogamulizumab